Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Fineline Cube Jul 2, 2026
Company Deals Digital

Insilico Medicine and Takeda Launch $600M Strategic AI Drug Discovery Collaboration – Pharma.AI Platform to Drive Candidate Identification for High-Potential Therapeutic Targets

Fineline Cube Jul 2, 2026
Company Deals

Nona Biosciences and Lonza Forge Strategic Alliance to Develop Best-in-Class Blood-Brain Barrier Penetration Technology for CNS Therapeutics

Fineline Cube Jul 2, 2026
Company Deals

Ipsen to Acquire Memo Therapeutics for €200M Plus Milestones, Gaining Phase II BK Virus Antibody Potravitug for Transplant Nephropathy

Fineline Cube Jul 2, 2026
Company Deals

Ribo Life Science Achieves First Milestone in siRNA Collaboration with Madrigal for MASH Therapeutics

Fineline Cube Jul 2, 2026
Policy / Regulatory

China’s CDE Unveils 108th Batch of Reference Preparations for Generic Drug Evaluation, Adds 28 New Drugs

Fineline Cube Jun 29, 2026
Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Fineline Cube Jul 2, 2026
Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Fineline Cube Jul 2, 2026
Company Deals

Pediatrix Therapeutics Licenses Tris Pharma’s ADHD Portfolio for Greater China

Fineline Cube Dec 2, 2022

China-based Pediatrix Therapeutics announced a licensing agreement with US firm Tris Pharma, Inc., obtaining exclusive...

Policy / Regulatory

Hainan’s New Regulations on Medical Devices in Boao Lecheng to Take Effect in 2023

Fineline Cube Dec 2, 2022

The “Regulations on the Administration of Medical Devices in Boao Lecheng International Medical Tourism Pilot...

Company Drug

Kintor’s KX-826 Reaches Primary Endpoint in Phase II Study for Female AGA

Fineline Cube Dec 2, 2022

China-based Kintor Pharmaceutical Ltd (HKG: 9939) announced that the Phase II clinical study for its...

Company Medical Device

Sansure Biotech’s Pertussis Detection Kit Approved by NMPA

Fineline Cube Dec 2, 2022

China-based molecular diagnostics specialist Sansure Biotech Inc. (SHA: 688289) announced that it has obtained medical...

Company Drug

Simcere’s Edaravone, Borneol Sublingual Tablets Reach Phase III Efficacy Endpoint

Fineline Cube Dec 2, 2022

Jiangsu Simcere Pharmaceutical Co., Ltd (HKG: 2096) announced that a Phase III clinical study for...

Digital R&D

AI Model for Early Alzheimer’s Detection Using Retinal Photographs Published

Fineline Cube Dec 2, 2022

A joint Singapore-UK-Hong Kong research team has published details of an AI-based deep learning model...

Company Deals

XJTLU and University of Liverpool Launch Joint Centre for Pharmacology and Therapeutics

Fineline Cube Dec 2, 2022

The Suzhou-based Xi’an Jiaotong-Liverpool University (XJTLU) and the UK’s University of Liverpool earlier this month...

Company Deals

Yifan Pharmaceutical Licenses F-627 to Acrotech for US Distribution

Fineline Cube Dec 2, 2022

China-based Yifan Pharmaceutical Co., Ltd (SHE: 002019) announced the establishment of a licensing agreement with...

Company Deals Digital

Nans Tech Secures Series A Funding for Brain Dysfunction Digital Therapies

Fineline Cube Dec 1, 2022

Nans Tech, a brain dysfunction digital therapy developer based in Hangzhou, reportedly raised “tens of...

Company Deals

Aclaris Therapeutics Licenses JAK Inhibitor ATI-1777 to Pediatrix for Greater China

Fineline Cube Dec 1, 2022

US-based Aclaris Therapeutics Inc. (NASDAQ: ACRS) and Shanghai firm Pediatrix Therapeutics Inc. entered into a...

Policy / Regulatory

China’s NMPA Issues New GSP Appendix for Drug Retailing Quality Management

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released “Good Supply Practice (GSP) Appendix 6: Quality...

Company Drug

ImmuneOnco Initiates Phase II Clinical Study for CD47 Antibody IMM01

Fineline Cube Dec 1, 2022

ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced the initiation of a Phase II clinical study...

Policy / Regulatory

China’s NMPA Seeks Feedback on Drug Quality Management Provisions

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a draft proposal titled “Provisions on the...

Company Deals

Luye Pharma’s Shandong Boan Bio Files for Hong Kong IPO

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd, has filed...

Company Deals

Luca Healthcare Partners with Cambridge Cognition to Launch Cognitive Tools in China

Fineline Cube Dec 1, 2022

China-based digital health solutions provider Luca Healthcare has announced a strategic partnership and license agreement...

Company Drug

Luye Pharma’s Biosimilar to Amgen’s Xgeva Launched in China

Fineline Cube Dec 1, 2022

China-based Luye Pharma Group (HKG: 2186) has announced the first prescription of its biosimilar version...

Company Medical Device

Assure Tech Wins Japanese PDMA Approval for Pen-Type COVID-19 Antigen Test

Fineline Cube Dec 1, 2022

China-based Assure Tech (Hangzhou) Co., Ltd (SHA: 688075) has announced receiving marketing approval from Japan’s...

Company Drug

Double-Crane Pharma Gains NMPA Approval for COVID-19 Drug CX2101A Clinical Trials

Fineline Cube Dec 1, 2022

China Resources Double-Crane Pharmaceutical Co., Ltd (SHA: 600062) has announced receiving clinical trial approval from...

Company Medical Device

Lepu Medical Wins NMPA Approval for Disposable Pressure Microcatheter

Fineline Cube Dec 1, 2022

China-based cardiovascular disease solutions provider Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003) has announced...

Policy / Regulatory

China’s NMPA Shifts to Electronic Drug Filings from January 2023

Fineline Cube Dec 1, 2022

China’s National Medical Products Administration (NMPA) has released a notification indicating the initiation of electronic...

Posts pagination

1 … 616 617 618 … 690

Recent updates

  • Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program
  • Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy
  • Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched
  • TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations
  • TransThera Advances Phase II Trial of Selective BTK Inhibitor TT-01488 with Anti-CD20 Antibodies for Mantle Cell Lymphoma – Novel Non-Covalent Approach Shows Enhanced Safety Profile
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hangzhou Adamerck’s Aom0498 Receives NMPA Approval as China’s First Homegrown Neuromuscular Blockade Reversal Agent – Completing Decade-Long National Innovation Program

Company Deals

Junshi Biosciences Licenses Anti-IL-17A Antibody Roconkibart to Fosun Wanbang for Greater China – $1.34B Deal Secures Commercialization of Phase III-Ready Psoriasis Therapy

Company Drug

Jingxin Pharmaceutical Secures NMPA Approval for China’s First Generic Cariprazine in Schizophrenia – Capturing Market Opportunity as Reference Product Remains Unlaunched

Company Drug

TransThera Completes Patient Enrollment in Global Phase III Trial of Tinengotinib for Advanced Cholangiocarcinoma – Multi-Kinase Inhibitor Backed by Multiple Regulatory Designations

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.